NR1D1 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-09. Anything still debated is marked as such rather than presented as settled.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
It was discovered in the 19th century that salt mixed with nitrates (such as saltpeter) would color meats red, rather than grey, and consumers at that time then strongly preferred the red-colored meat. The food hence preserved stays healthy and fresh for days avoiding bacterial decay.
Diabetes management concentrates on keeping blood sugar levels close to normal, without causing low blood sugar. This can usually be accomplished with dietary changes, exercise, weight loss, and use of appropriate medications (insulin, oral medications). Learning about the disease and actively participating in the treatment is important, since complications are far less common and less severe in people who have well-managed blood sugar levels. The goal of treatment is an HbA1C level below 7%. Attention is also paid to other health problems that may accelerate the negative effects of diabetes. These include smoking, high blood pressure, metabolic syndrome, obesity, and lack of regular exercise. Specialized footwear is widely used to reduce the risk of diabetic foot ulcers by relieving the pressure on the foot. Foot examination for patients living with diabetes should be done annually which includes sensation testing, foot biomechanics, vascular integrity and foot structure. Concerning those with severe mental illness, the efficacy of type 2 diabetes self-management interventions is still poorly explored, with insufficient scientific evidence to show whether these interventions have similar results to those observed in the general population.
The hypothesis that melatonin synthesis occurs within mitochondria and chloroplasts suggests an evolutionary and functional significance of melatonin in cellular energy metabolism and defense mechanisms against oxidative stress, reflecting the molecule's ancient origins and its multifaceted roles across different domains of life.
Diclofenac in animals has environmental effects. It is toxic, for example, to scavenging birds. Too, residues of the drug are found in marine and freshwater organisms, contaminated by agricultural runoff containing diclofenac. The medication has been banned for veterinary use in several countries; India restricted its use in 2006. Meloxicam is an alternative which is safer for wildlife. Veterinary use in livestock resulted in a sharp decline in the vulture population in the Indian subcontinent – a 95% decline by 2003 and a 99.9% decline by 2008. Vultures are long-lived and slow to breed. They start breeding only at the age of six and only 50% of their young survive. Even if the Indian government ban is fully implemented, it will take many years to revive the vulture population. The mechanism of toxicity in vultures is presumed to be kidney failure; however, toxicity may be due to direct inhibition of uric acid secretion in vultures. Vultures eat the carcasses of livestock that have been administered veterinary diclofenac, and are poisoned by the accumulated chemical, as vultures do not have a particular enzyme to break down diclofenac. At a meeting of the National Wildlife Board in March 2005, the Government of India announced it intended to phase out the veterinary use of diclofenac. Steppe eagles have the same vulnerability to diclofenac as Old World vultures and are therefore at similar risk from its effects. In contrast, New World vultures, such as the turkey vulture, can tolerate at least 100 times the level of diclofenac that is lethal to Gyps species.
== Further reading == Madelain V, Nguyen TH, Olivo A, de Lamballerie X, Guedj J, Taburet AM, et al. (August 2016). "Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials". Clin Pharmacokinet. 55 (8): 907–23. doi:10.1007/s40262-015-0364-1. PMC 5680399. PMID 26798032.
Sources: en.wikipedia.org
=== Bottom-up and top-down methods === Small graphene structures, such as graphene quantum dots and nanoribbons, can be produced by "bottom-up" methods that assemble the lattice from organic molecule monomers (e. g. citric acid, glucose). "Top-down" methods, on the other hand, cut bulk graphite and graphene materials with strong chemicals (e. g. mixed acids).
low: hs-CRP level under 1.0 mg/L average: between 1.0 and 3.0 mg/L high: above 3.0 mg/L Normal levels increase with aging. Higher levels are found in late pregnant women, mild inflammation and viral infections (10–40 mg/L), active inflammation, bacterial infection (40–200 mg/L), severe bacterial infections and burns (>200 mg/L). CRP cut-off levels indicating bacterial from non-bacterial illness can vary due to co-morbidities such as malaria, HIV and malnutrition and the stage of disease presentation. In patients presenting to the emergency department with suspected sepsis, a CRP/albumin ratio of less than 32 has a negative predictive value of 89% for ruling out sepsis. CRP is a more sensitive and accurate reflection of the acute phase response than the ESR (erythrocyte sedimentation rate). ESR may be normal while CRP is elevated. CRP returns to normal more quickly than ESR in response to therapy.
== Development and current usage == Livia S. Eberlin, Ph.D., an Assistant Professor of Chemistry at the University of Texas at Austin, first reported the invention of the MasSpec Pen in 2017. Within her laboratory, the device has been used to analyze human tissue biopsies, including normal and cancerous breast, lung, ovarian, and thyroid samples. The MasSpec Pen is currently being evaluated for use on freshly excised tissue biopsies and for intraoperative use during oncology surgeries. The MasSpec Pen has been licensed to Genio Technologies, Inc., a subsidiary of MS Pen Technologies, Inc.
Tetra Pak also works with Chinese schools to regulate storage, distribution and recycling of school milk. They certified 53 schools as 'Promotion Model Schools' in 2017 and aimed to certify 50 more schools in 2018. During the COVID-19 pandemic, Tetra Pak helped maintain the delivery of school feeding programmes via online orders and non-contact delivery methods. The Tetra Laval Group donates 10 million Euro to various voluntary organisations supporting health care systems. Following the 2022 Russian invasion of Ukraine, Tetra Pak condemned the invasion and Tetra Laval donated 10 million Euro towards organisations including UNICEF, Save The Children, The Red Cross and Doctors Without Borders.
=== Food safety === Faced with the problem of how and what to feed an astronaut in a sealed capsule under weightless conditions while planning for human spaceflight, NASA enlisted the aid of The Pillsbury Company to address two principal concerns: eliminating crumbs of food that might contaminate the spacecraft's atmosphere and sensitive instruments, and assuring absolute absence of disease-producing bacteria and toxins. Pillsbury developed the Hazard Analysis and Critical Control Points (HACCP) concept to address NASA's second concern. HACCP is designed to prevent food safety problems rather than to catch them after they have occurred. The U.S. Food and Drug Administration has applied HACCP guidelines for the handling of seafood, juice, and dairy products.
Sources: en.wikipedia.org
Commercial growers usually harvest the tulip bulbs in late summer and grade them into sizes; bulbs large enough to flower are sorted and sold, while smaller bulbs are sorted into sizes and replanted for sale in the future. Because tulip bulbs do not reliably come back every year, tulip varieties that fall out of favour with present aesthetic values have traditionally gone extinct. Unlike other flowers that do not suffer this same limitation, the tulip's historical forms do not survive alongside their modern incarnations. Tulip bulbs are typically planted around late summer and fall, in well-drained soils. Tulips should be planted 10 to 15 cm (4 to 6 inches) apart from each other. The recommended hole depth is 10 to 20 cm (4 to 8 inches) deep and is measured from the top of the bulb to the surface. Therefore, larger tulip bulbs would require deeper holes. Species of tulips are normally planted deeper.
== AFL career == Pears was drafted by Essendon with pick 23 in the 2007 national draft and debuted in 2008. He played the role of a key position defender in his second season, taking on big dominant forwards such as Daniel Bradshaw, Jarryd Roughead and Justin Koschitzke. After playing on Brendan Fevola in round 13, 2009, he was the round nominee for the Rising Star. Off-season surgery on a foot fracture that set back his return to senior football saw Pears’ bad run with injury continue in 2011. He played his first game of the year against North Melbourne in round 13, but saw his season further stifled with injury after breaking his lower leg and then straining his hamstring in the elimination final. Injury continued to force him to sit on the sidelines in the years after, managing 23 games in the next four seasons. Then on 12 January 2016 Pears was named as one of 34 past and present Essendon players found guilty over their use of illegal supplements during the 2012 AFL season. As a result, Pears was suspended for two years, which, as a result of backdating, saw him suspended between January and November 2016, which meant he missed the entire 2016 AFL season. He did not return to the AFL after his suspension, announcing his retirement from the league on 8 September 2016 to pursue a career in firefighting.
Little research has been focused on the suppository (anal insertion), also known as "plugging" or "boofing". These methods of administration are commonly carried out using an oral syringe. Heroin can be dissolved and withdrawn into an oral syringe which may then be lubricated and inserted into the anus or vagina before the plunger is pushed. The rectum or the vaginal canal is where the majority of the drug would likely be taken up, through the membranes lining their walls.
== Metabolism == The following section describes the ADME (absorption, distribution, metabolism and excretion) of α-bungarotoxin. There is limited information available on the pharmacokinetics of this neurotoxin. More research is needed to be able to fully understand the metabolism of this neurotoxin inside the body. Absorption: α-bungarotoxin enters the body after envenomation into the bloodstream at the bite site. Through the venom, a mixture of proteins and different molecules enter the body. Distribution: Once in the bloodstream, α-bungarotoxin circulates throughout the body. Its distribution may be influenced by factors such as blood flow, tissue permeability, and the presence of binding proteins. Additionally, knowing it binds to nAChRs, it can be predicted where the neurotoxin would be present: neuromuscular junctions, autonomic ganglia, peripheral nerves, and adrenal medulla. One of the main locations would be also the central nervous system (CNS), including the brain. Specific regions such as the hippocampus, cortex, and basal ganglia contain these receptors. Metabolism: The metabolic pathways of this neurotoxins have not been fully understood yet, however, it is thought to be metabolised in the liver. Researching venom metabolism is challenging due to the multiple components present in it. Toxins that are not bound may undergo elimination through opsonization by the reticuloendothelial system, mainly involving the liver and kidneys, or they may undergo degradation through cellular internalization facilitated by lysosomes.
Collins described her return to the show as "redemption" after withdrawing from her original series, comparing herself to Lara Croft and noted that although the series was tougher this time around, she felt she had "unfinished business" and ultimately "shut it down". She entered camp on the second day of the series alongside Craig Charles, who had also appeared on her original series. Collins completed a helicopter ride into camp, before she and Charles took part in an eating trial, which was won by the latter. She resided in the basic camp "Savannah Scrub" alongside Adam Thomas, Beverley Callard and Seann Walsh for several days, until they joined the main camp after completing a trial in which they were situated in water tanks and had to transport keys to one another. Following her arrival in main camp, Collins fell out of her hammock during one of the episodes. She completed her third trial alongside Scarlett Moffatt, during which time the camp was split into teams. She ultimately lost this trial; however her team the "Rhinos" were victorious and ultimately won a banquet and a trip on safari. Following a safety chain elimination in which Collins was saved by Jimmy Bullard and David Haye was eliminated, Haye then had to choose another campmate to leave alongside him. He chose Collins, who ultimately became the third campmate to be eliminated from the series after spending nine days in camp. Later in the year, Collins is set to begin starring in a Sky One reality series, Gemma Collins: Everything.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.